NCT01514370View on ClinicalTrials.gov

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Multiple Sclerosis

Interventions

DRUG

IFN beta 1a 44 mcg TIW

Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.

DRUG

Curcumin

Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.

DRUG

Placebo

Subjects received placebo matched to curcumin orally twice a day for 24 months.

Trial Locations (1)

80131

Investigational Site, Naples

All Listed Sponsors

collaborator

Merck Serono S.P.A., Italy

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01514370 - Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a | Biotech Hunter | Biotech Hunter